Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS), joins a16z Bio + Health general partner Jorge Conde.

Together, they talk about how AI could transform drug discovery and development at a large biopharma company—and how a company might have to adapt to harness AI; modalities they’re excited about; and Greg’s do’s and don’ts for startups looking to partner with a company like BMS.